论文部分内容阅读
本文报告急性脑梗塞260例,其中160例急性脑梗塞应用尿激酶10万~U+N·S100ml,静脉滴注,q12h×10天;100例应用Svate-Ⅲ 2~U+N·S100ml,静脉滴注一次/日×15天,两组同时应用Ca~(++)拮抗剂,稀释疗法及脑细胞赋形剂治疗。结果尿激酶组基愈率为65%,显效率90.63%,总有效率达96.26%,非常显著优于Svate-Ⅲ的51%、75%及89%。结果提示尿激酶治疗急性脑梗塞在注意出血倾向发生时是安全、有效的。
This article reports 260 cases of acute cerebral infarction, of which 160 cases of acute cerebral infarction urokinase 100,000 U ~ N · S100ml, intravenous infusion, q12h × 10 days; 100 cases of Svate-Ⅲ 2 ~ U + N · S100ml, intravenous Instillation / day × 15 days, two groups of simultaneous application of Ca ~ (++) antagonist, dilution therapy and brain cell excipients. Results The urokinase group had a cure rate of 65%, a markedly effective rate of 90.63% and a total effective rate of 96.26%, which was significantly better than 51%, 75% and 89% of Svate-Ⅲ. The results suggest that urokinase in the treatment of acute cerebral infarction is safe and effective in paying attention to the occurrence of bleeding tendency.